Gav retweeted
dunno seems a shame to not check it out when it could contain your next 100x
7 day free trial btw
Gav retweeted
Linn's Leverage #1123 is out: (Link in tweet below)
@boros_fi
@pendle_fi
@Chainflip
@mezzanine_fi
@Mantle_Official
@StaticsProtocol
@GammaSwapLabs
Like/Repost to support:
Little known fact:
BTC has NEVER been beaten by stocks over a 4 year investment duration. Even if you bought the top.
In fact, at 42% CAGR, BTC beats the undisputed champion of hedge funds, Renaissance Technologies, who delivered 39% to their investors.
Gav retweeted
Linn's Leverage #1118 is out: (Link in tweet below)
@boros_fi
@pendle_fi
@Chainflip
@mezzanine_fi
@Mantle_Official
@GammaSwapLabs
Like/Repost to support:
Gav retweeted
Staying ahead of Narrative Rotations is the key to unlocking the next 20-100x
A majorly overlooked indicator is the "Pendle Factor"
Let's look at all the narratives they've been a major player in:
→ LSTs
→ LRTs
→ points markets
→ BTC-fi
→ yield-bearing stablecoins
→ RWA / institutional fixed yield
→ PT collateral & looping
→ memestonks
Add to this:
- PT is now a THE primitive for onchain fixed yield integrated as collateral across Aave, Morpho, Euler, + insti curators (Wintermute’s Armitage) running vaults on top reaching ~$60M in TVL
- For RWAs pendle has ~45 live RWA markets, 19 of them above $10M with Paxos, Sky, Agora, private credit, receivables, even tokenized stocks
- Every new listing frequently offers ze best fixed rates AND early entries capture rates before they compress The early Pendle users eat good with the launch of new pools
- ~$1.2B TVL in one of the bloodiest drawdowns in crypto plus fees near ATH while the market chopped (good for holders)
Linn's strategy is simple: Pay attention to what is on Pendle + Hold and Stake ethereum:0x808507121b80c02388fad14726482e061b8da827
linn has been holding an ungodly amount of pendle for years now because there simply isn't a future where it isn't up insane multiples from here, pendle is one of the grittiest, hardest working, relentless teams in crypto and linn would be saying exactly the same things even if linn wasn't a tier 1 kol supreme for pendle
Gav retweeted
Linn's Leverage #1101 is out: (Link in tweet below)
@boros_fi
@pendle_fi
@Hookrfun
@Theo_Network
@Mantle_Official
@StaticsProtocol
Like/Repost to support:
Gav retweeted
I am a FIRST generation Aussie. The child of a migrant. The political left is using the Monoculture hysteria as a fig leaf to avoid dealing with the things it needs to; namely, ensuring cultural and values alignment with new migrants, and guarding Australia’s culture of tolerance, freedom and democracy. Dont @ me. I’m right on this one.
Gav retweeted
Landmines in @JEChalmers Budget 💣
@parnellpalme McGuinness exposes the rushed CGT changes that will hammer share investors: gains taxed hard, losses barely offset. Share portfolios crushed, aspiration attacked, economic vandalism confirmed.
@DerekFranc90653 called it on day one. Treasury modelling is a disgrace. This insane tax on aspiration must be stopped.
Read this 👇 #AussieDreamKiller #AspirationTax
Gav retweeted
They aren’t “Asian” grooming gangs.
They aren’t even just Pakistani gangs.
But they are always Muslim.
It is gangs of Muslim men who groomed, abused, raped, sodomised, tortured, kidnapped, and murdered hundreds of thousands little girls across the UK.
Grooming gangs are usually Pakistani. Some gang members have been Iraqi, Afghan, or Iranian too.
But they are always Muslim.
That isn’t Islamophobic. It’s reality.
Gav retweeted
We must stop this insane new tax on capital gains. Sign 👇 wilsonassetmanagement.com.au…
Treasurer @JEChalmers is a wealth destroyer & enemy of Australia. Unlike our Treasurer, Richard Holden is a highly regarded economist with a PhD in economics (from Harvard).
Gav retweeted
The LARGEST human ivermectin cancer study EVER conducted found 84% of cancer patients declared COMPLETE REMISSION, TUMOR SHRINKAGE, or HALTED TUMOR GROWTH.
Our study is now PEER-REVIEWED and PUBLISHED by the International Institute of Anticancer Research.
The tide is turning.
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson


























